Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation.
about
Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent associationAkt binds to and phosphorylates phospholipase C-gamma1 in response to epidermal growth factorPLC-gamma1 and Rac1 coregulate EGF-induced cytoskeleton remodeling and cell migrationHrs regulates early endosome fusion by inhibiting formation of an endosomal SNARE complexNeuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1Structure-function relationships of ErbB RTKs in the plasma membrane of living cellsAt the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of boneStructural Insights into the Down-regulation of Overexpressed p185her2/neu Protein of Transformed Cells by the Antibody chA21The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor FamilyP130Cas attenuates epidermal growth factor (EGF) receptor internalization by modulating EGF-triggered dynamin phosphorylationRegulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomesRegulation of EGF-induced phospholipase C-gamma1 translocation and activation by its SH2 and PH domainsMarked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibitionClathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus.Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycinThe HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartmentsQuantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction.Regulation of ErbB2 receptor status by the proteasomal DUB POH1.Quantifying the effects of co-expressing EGFR and HER2 on HER activation and trafficking.EGFR may couple moderate alcohol consumption to increased breast cancer risk.The constitutive activity of epidermal growth factor receptor vIII leads to activation and differential trafficking of wild-type epidermal growth factor receptor and erbB2Role of receptor tyrosine kinases and their ligands in glioblastoma.HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanismsEGFR signaling in breast cancer: bad to the bone.Differential regulation of transcription factors by location-specific EGF receptor signaling via a spatio-temporal interplay of ERK activation.A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells.Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisA system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions.Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological responseThe epidermal growth factor receptor family: biology driving targeted therapeutics.Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodiesEndocytosis and intracellular trafficking of ErbBs.Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.Bioengineering embryonic stem cell microenvironments for the study of breast cancerIdentification of an AAA ATPase VPS4B-dependent pathway that modulates epidermal growth factor receptor abundance and signaling during hypoxia.In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption
P2860
Q24297029-F223869F-A373-46EE-8290-E5D00D9627D5Q24306906-05D07C85-8117-4CDE-B855-9966168E0EC5Q24318343-097B714C-397A-4CE1-B8E9-9653FBA313F6Q24675805-4DF6582D-2184-4ED7-AE79-377E3DA32CB1Q24681497-37220627-440A-4D47-B075-CCC6FD1FC0DDQ26853162-5664492E-F8E7-40A6-944F-14B0F8C83E1CQ26866067-C2A1CCBA-6B95-4EC8-8AE7-4F0050CB1EBFQ27670462-F5BF24F3-96AD-4750-8687-B3AEF11E225CQ28073335-E7456E5F-B795-4C72-AEB1-5F7923C745E8Q28478184-CF415719-2E1B-4FAF-AF9F-4B695314C022Q28511379-5B1C3B86-2148-4502-BB54-F6997654C8E6Q28610688-0AF26656-1F70-40B9-89E6-685ED0495E45Q28829301-2154E61A-9EBB-4916-A890-2FF42752EE2BQ30439237-01668180-68B7-43D8-8D93-C9446861E2FFQ30479942-B71199CE-D538-4294-9ED0-9F3CC7E551D0Q30839490-8C564453-2518-4463-BDCE-547AEA074B79Q31107044-EC5FE973-EFCA-4E88-88FA-CAA2177BED12Q33196419-344A37AF-7602-4A3D-BDFA-1EF8E3BD9BB4Q33444766-E505B679-37DB-490A-83E7-2D48B83A251FQ33827628-6A97AC3E-0F8A-4645-B902-FB34966F4DD3Q33858538-C89633A5-4EE8-4EBD-9B34-F05D02CD647CQ33867510-41B27992-A85F-4F60-B9BC-5480197A6F78Q33883849-8D1CB749-20A0-4F45-8DFA-B37E6DD79392Q34183239-6B595841-88DB-4D32-B735-26E2E1C9E75CQ34348232-99A9C834-B9F5-4782-9535-9ED91408096FQ34415844-58C9027F-5765-4AC9-A385-E6EEBBF08AEEQ34430965-EF9D9886-4C14-4F9A-A00E-1D666F39D27CQ34477986-20344132-3505-4132-84AF-76DB9D9A195FQ34483533-6A92B174-D374-463A-BFC1-E2C0940C0529Q34483541-995EEC8A-488B-4851-9B3F-F18EBCCF8C03Q34493341-305727DE-48EE-4494-8574-B2A3874C3913Q34587922-3AD162F7-A91D-47D0-ABD9-286E895060B5Q34600838-E1EF5EE0-789A-4116-8189-BB7B98913849Q34692233-2BD20741-C536-49DB-9992-AAE29D965199Q34719632-D9B1AC64-B14E-45DE-960E-C32FD2D6816FQ34827744-C301E048-9B34-4086-A193-9F50B0751776Q35001415-C6E17EA5-1DD5-408E-9A11-E4F0149F4D30Q35600151-B6E22ECF-24DA-41ED-955C-478F9D815B69Q35806672-BDB7264B-E882-458C-953E-491F623708B1Q35836035-A303A308-7323-4732-A260-40E8781A9BD9
P2860
Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Endocytosis deficiency of epid ...... n response to EGF stimulation.
@en
type
label
Endocytosis deficiency of epid ...... n response to EGF stimulation.
@en
prefLabel
Endocytosis deficiency of epid ...... n response to EGF stimulation.
@en
P2093
P2860
P356
P1476
Endocytosis deficiency of epid ...... n response to EGF stimulation.
@en
P2093
P2860
P304
P356
10.1091/MBC.10.5.1621
P577
1999-05-01T00:00:00Z